Clinical trial
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess Efficacy and Safety of Pregabalin in Willis-Ekbom Disease/Restless Legs Syndrome
NCT04161027 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess Efficacy and Safety of Pregabalin in Willis-Ekbom Disease/Restless Legs Syndrome
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 24, 2020
- Completion date
- April 4, 2022
- Enrollment
- 116 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.